s3-e35.4 - liver science at #ilc2022: commercial benefits from the new liver science
Published 2 years ago • 28 plays • Length 12:36Download video MP4
Download video MP3
Similar videos
-
1:04:23
s3-e35 - #ilc2022 look back: liver science and fibrosis
-
15:58
s3-e35.2 - liver science at #ilc2022: the interplay of stellate cell dynamics and hepatic fibrosis
-
11:24
s3-e35.3 - liver science at #ilc2022: stellate cells, omics and novel receptor targets
-
17:31
s3-e35.1 - liver science at #ilc2022: circadian rhythm and stellate cells
-
11:06
s3-e35.5 - liver science at #ilc2022: mid-range impact of advances
-
1:01:14
s3-e11 - nail-nit and the path from non-invasive testing to outcomes
-
8:30
water challenges for hydrogen production (apac hydrogen summit & exhibition '23)
-
3:25
circadian science: fighting cancer with our biological clocks
-
53:38
apoe, apoe4, cholesterol, ldl & insulin resistance - links to heart disease & dementia
-
54:22
s3-e40.5 - from the vault: why cirrhosis matters in clinical trial strategy
-
12:17
s3-e24.3 - focus on preventative hepatology
-
11:44
s3-e37.4 - the "pincer movement" in cirrhosis technology: patient support vs high-end medtech
-
12:04
s3-e51.3 - aasld 2022: a preview of patient advocate coverage on liver health equity
-
14:27
s4-e6.3 - linking cardiovascular outcomes to fatty liver and utilizing fib-4 in australia
-
14:01
s3-e58.2 - expanding benefits in fibroscan use and integrating digital tools
-
42:40
s4-e29 - easl congress 2023: real-time review part 1
-
12:23
s4-e33.3 - steatotic liver disease, hcc and mechanisms of fibrosis resolution
-
16:37
s4-e33.4 - more presentation insights on frequency of testing, nits and biopsy
-
11:39
s4-e40.3 - which test is best for which patients?
-
14:05
s4-e4.6 - donna cryer on aligning regulatory science and expanding avenues for advocacy
-
15:29
s4-e27.4 - previewing easl congress 2023 with louise campbell: frontline screening
-
10:34
s4-e35.3 - strengthening patient involvement, nit development and lessons from ai